Paradigm4 Launches REVEAL: Proteomics to Transform the Search for Protein Isoform Biomarkers

BOSTON — Paradigm4 has today unveiled REVEAL™: Proteomics, the newest use case specific app powered by the Paradigm4 FLASH™ high-performance bioinformatics platform.

REVEAL: Proteomics unlocks the power of advanced mass spec proteomics by simplifying cross sample and cross study searching for protein isoforms as potential biomarkers for drug response or disease progression. REVEAL: Proteomics directly addresses the time-consuming data science challenge of preparing individual data sets for analysis, manual curation of identities, and the limitations of how many samples can be compared. The REVEAL: Proteomics app allows hypothesis testing in seconds across an unlimited number of studies. The new application aims to streamline disease research with integrated protein-gene mappings between HUGO and ENSEMBL ontologies, enabling analysis in an ad hoc manner without connecting to external websites.

REVEAL: Proteomics is built on top of Paradigm4’s FLASH next generation analytics platform, designed for rapid data slicing to enable scientific data modelling, storage, and population-scale computation. The efficient storage architecture of FLASH and Paradigm4’s focus on optimal execution speed means the total cost of ownership (TCO) is predicable, and significantly lower than other bioinformatics ecosystem approaches. REVEAL: Proteomics ensures that data and analysis are shareable with colleagues globally through Paradigm4’s high-throughput elastic file system, flexFS.

Paradigm4’s REVEAL apps are a suite of use case-specific applications that power discovery from population-scale to small studies. Other apps developed by Paradigm4 include REVEAL: Single Cell, which enables users to build a multidimensional understanding of disease biology, scale to handle more samples from patients, with more cells, and readily assess key biological hypotheses for target evaluation, disease progression, and precision medicine.

Zachary Pitluk, Ph.D., VP of Life Sciences and Healthcare at Paradigm4, commented: “REVEAL: Proteomics makes the use of protein isoforms practical for understanding diseases and drug response. It allows the testing of hypotheses against your entire collection of studies and the broad range of conditions and treatments. REVEAL: Proteomics truly enables protein isoform biomarker discovery and use.”

“Our high-performance computing platform empowers data scientists to perform deeper analysis in an ad hoc manner. The REVEAL: Proteomics app is the latest addition to our suite of REVEAL applications, as we look to make it easier for researchers to search and access their proteomic data and transform the discovery of new biomarkers.”

For more information about Paradigm4, please contact or visit

About Paradigm4

Paradigm4 translates bioinformatics data into real-world discoveries. Its high-performance data management and scalable computing solutions are being used by pharma and biotech companies to uncover new insights in a way that is both interactive and cost-effective. The integrative platform allows users to interrogate and explore data for discovery, as well as facilitating ad hoc analysis. With the REVEAL suite of extensible cloud-driven apps, users can power massively scalable analytics and machine-learning on multimodal data to propel their drug discovery.


Paradigm4 launches flexFS

Paradigm4, an integrated scientific data analytics company, has launched flexFS, its elastic cloud file system for flexible and more resource-efficient data storage and scalable computing.

54gene Enlists Paradigm4’s Science-Ready Data Solution for its African Health Information Ecosystem

12 JANUARY 2021: Paradigm4, specialist in scientific data management and scalable computation, has signed an agreement with 54gene, a health technology company deriving insights from the world’s most diverse populations to solve some of healthcare’s biggest challenges. The agreement will allow 54gene to use Paradigm4’s REVEALTM Biobank app to explore, characterize and query the growing repository of data that constitutes 54gene’s pioneering African Health Information Ecosystem, which is a highly curated, unique data source of clinical, phenotypic and genetic information from which insights can be generated that lead to new treatments and diagnostics.

Africa contains more genetic diversity than any other continent, however, fewer than 3% of the genomes analyzed to date have come from Africans1. As a result, information that could prove beneficial to the improvement of healthcare for all populations across the world, may be missed. 54gene is working to change this by collaborating with researchers on the African continent to include the world’s most genetically diverse population in global genomics research that can be used to power drug discoveries and derive therapeutic insights in healthcare for the benefit of all populations.

The REVEALTM Biobank app that 54gene will use is built on top of Paradigm4’s novel computational database engine, SciDBTM, which is purpose-built to handle large-scale heterogeneous scientific data. The REVEALTM Biobank provides researchers with an easy-to-use way to access their high-resolution, multi-dimensional and multi-attribute data. Users can fluidly combine diverse data sources like genotypic, phenotypic, biomedical imaging, and health records for cross-validation and enrichment. The app is also optimized for scalable advanced analytics and machine learning.

Marilyn Matz, co-founder and CEO of Paradigm4, commented:

We’re delighted to be partnering with 54gene on this exceptionally important project to create an inclusive bank of genetic data for African people that has the potential to change the way pharma companies develop personalized medicine. Our REVEALTM Biobank app accelerates integrative, multimodal, longitudinal, population-scale data science exploration and discovery, which will provide 54gene with an unrivalled ability to interrogate its extensive and diverse datasets.

Delali Attiogbe Attipoe, Chief Operating Officer at 54gene, commented:

We discovered Paradigm4 via its work with the UK Biobank and were impressed by REVEALTM Biobank’s cohort selector tool and R API with complex computing capacity. This will help us conduct detailed analysis of a variety of genotypic and phenotypic data within our African Health Information Ecosystem. Working with Paradigm4 and its intuitive app will allow us to uncover genetic connections and associations that will help support the development of therapeutics for a variety of diseases. By better understanding the genetic drivers of disease, we can ensure that African people and the global community benefit from cutting-edge medical innovation developed from the insights we have generated.”

For more information about Paradigm4, email


BioPharma Trend: A new way to work with data in life sciences

Interview with Marilyn Matz, CEO and Co-founder at Paradigm4, and 2020 NACD Directorship 100™ honoree, and her colleague Dr. Zachary Pitluk, VP of Life Sciences and Health Care at Paradigm4.

Founded by renowned database researcher, Turing Award laureate MIT Professor Michael Stonebraker, Paradigm4 is not just any data analytics company in the Life Sciences. The organization is built on the decades of pioneering research in database design and possesses unique technological know-how in scientific data management and scalable computation.